You brief the board and the CEO on where the portfolio stands, where the risk sits, and where to place the next bet — too often from a deck that was stale before it was printed. ClinicaLister puts the whole trial portfolio in one live, drillable view — 590k+ trials from 18+ public sources — with phase mix, geographic exposure, patent-cliff risk, and competitor concentration one click from any single trial.
The highest-leverage things ClinicaLister does for a executive / vp clinical development.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| Portfolio review deck prep | One live dashboard of phase, status, geography, sponsor, drug, and safety that drills to any trial in a click. | App | hours → minutes for the status layer | High |
| Go/no-go & prioritization | Live phase and status alongside competitor concentration and IP risk, all drillable to the underlying trial. | App | faster context (internal data still needed) | High |
| Portfolio risk oversight | Field-level change monitoring across the trial record, with severity cards that trend period over period. | App | flips/terminations in hours; directional | High |
| Competitive briefing | A competitor-pipeline matrix and competitive-density-by-indication view, sourced and refreshed instead of hand-built into a static deck. | Both | kills the stale static deck; sourced | High |
| Patent-cliff / LoE strategy | A patent-cliff timeline bucketed by urgency, plus an IP-cliff-versus-market-size view and an on-demand exclusivity countdown. | Both | IP exposure at a glance | High |
| BD / licensing / M&A scans | Pipeline-depth and white-space views that surface under-contested indications and in-licensing targets, on request through your AI assistant. | MCP | structured target sourcing | High |
| Market sizing | Medicare-based market sizing your AI assistant assembles on demand — a commercial dimension the app doesn't chart. | MCP | commercial dimension the app doesn't chart | Medium |
| Pricing / reimbursement input | A pricing-intelligence read that pulls list price, government reimbursement, and physician-payment data into one picture. | MCP | pricing intel — unique to the graph | Medium |
| Investor / earnings prep | Pipeline-depth and differentiation views plus a regulatory-velocity scorecard, board-presentable with provenance intact. | Both | board-presentable, provenance-backed | High |
| Budget / resource allocation | Phase, therapeutic-area, and geography distributions as an input — the external half of the picture, not your internal costs. | App | supports — no cost / FTE data | Medium |
| US / EU footprint strategy | Country and region charts with EU-to-US trial linkage, and a cross-registry comparison of your footprint on both sides. | Both | geographic/regulatory exposure at a glance | High |
| Portfolio safety oversight | Aggregated adverse-event summaries and disproportionality signals across your drugs and competitors' — directional candidates, not causal proof. | Both | directional — candidates, not causal | Medium |
| React to competitor news | New-entrant and momentum tracking that flags sponsor moves and fresh registrations between your meetings. | MCP | early-warning between meetings | High |
| Ad-hoc CEO / board questions | Ask your AI assistant a plain-language question and get a sourced answer across the whole portfolio. | MCP | fast "what's our exposure to X?" | High |
| Cross-functional alignment | One shared, sourced factual picture every function works from. | Both | one source of truth | Medium |
Straight answers on where ClinicaLister stops today — so there are no surprises.
No one-line executive scorecard yet. Insight comes from interactive, drillable charts — not a curated headline KPI card or a single portfolio-diversification number you can screenshot into a deck.
"Real-time" means refreshed through the day, not streaming. Portfolio moves surface within hours of hitting the public registries, not the second they happen.
The external half, not your internals. Budget and spend, FTE load, actual-versus-target enrollment, and program costs live in your own systems — ClinicaLister brings the competitive and market half.
Market-size and pricing are US- and Medicare-anchored. Treat them as a directional proxy for addressable market, not a full global total-addressable-market model.
The richest commercial intel lives with your AI assistant, not the app. Market sizing, pricing, business-development, and momentum views come through the assistant — a dashboard-only executive won't see them.
Phase balance, geographic exposure, patent-cliff risk, and competitor concentration in one real-time dashboard — the whole portfolio at a glance, drillable to a single trial in a click, current the moment you open it.